Innovative Product Portfolio MedAlliance specializes in advanced drug-eluting balloons with proprietary micro-reservoir technology that provides controlled and sustained drug release, offering significant advantages in treating coronary and peripheral artery disease. This innovative technology positions the company as a leader in minimally invasive vascular interventions, opening opportunities with healthcare providers seeking cutting-edge solutions.

Strong Regulatory and Clinical Gains With FDA Breakthrough Device Designation and multiple CE Mark approvals, MedAlliance's products demonstrate validated safety and efficacy, facilitating easier access to markets worldwide. This regulatory milestone support establishes credibility and accelerates sales potential in both the U.S. and Europe, especially as clinical studies enroll large patient populations.

Strategic Acquisitions and Investments Recent acquisitions by Cordis and significant equity funding from CITIC Capital reflect strong investor confidence and financial backing, providing MedAlliance with resources to expand sales channels and invest in new markets. Leveraging this financial stability can enhance domestic and international sales efforts.

Growing Clinical Evidence The enrollment of over 1,660 patients in landmark studies like SELUTION DeNovo and ongoing trials demonstrates expanding clinical validation for MedAlliance’s products. This robust evidence base can be used to persuade healthcare institutions and payers to adopt SELUTION SLR devices, increasing sales opportunities.

Global Market Presence With offices in Switzerland, Germany, Singapore, the UK, and the USA, MedAlliance maintains a strategic international footprint, allowing for regional customization and market penetration. This global presence offers multiple entry points for sales expansion into emerging and established healthcare markets worldwide.